|
PCBD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.644230E-02 |
| Normal-vs-Stage3 |
1.56097357262297E-13 |
| Normal-vs-Stage4 |
1.62936331093988E-12 |
| Stage1-vs-Stage2 |
1.758850E-03 |
| Stage1-vs-Stage3 |
3.122400E-01 |
| Stage1-vs-Stage4 |
1.492260E-02 |
| Stage2-vs-Stage3 |
6.993300E-04 |
| Stage2-vs-Stage4 |
2.22319999999554E-05 |
| Stage3-vs-Stage4 |
1.331000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.382690E-03 |
| Normal-vs-Asian |
1.69929958993009E-10 |
| Caucasian-vs-AfricanAmerican |
4.162600E-01 |
| Caucasian-vs-Asian |
8.240400E-01 |
| AfricanAmerican-vs-Asian |
3.928800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.14590004152149E-09 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
1.076610E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62536650805123E-12 |
| Normal-vs-Age(41-60Yrs) |
2.03170813506404E-14 |
| Normal-vs-Age(61-80Yrs) |
1.32140000053127E-08 |
| Normal-vs-Age(81-100Yrs) |
3.358800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.550600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.210200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.834200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.955790E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.223200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.142000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.044000E-04 |
| Classical-VS-Follicular |
3.85339999997569E-06 |
| Classical-VS-Other |
4.420400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.24029997383701E-09 |
| Tall-VS-Other |
9.827700E-02 |
| Tall-VS-Normal |
1.11022302462516E-15 |
| Follicular-VS-Other |
4.051400E-01 |
| Follicular-VS-Normal |
4.830500E-04 |
| Other-VS-Normal |
1.165910E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.02930030954474E-10 |
| Normal-vs-N1 |
1.33226762955019E-15 |
| N0-vs-N1 |
5.63049999999787E-05 |
|
|
